BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q3 EPS of ($0.86), $0.13 better than the analyst estimate of ($0.99). Revenue for the quarter came in at $2.73 million versus the consensus estimate of $1.56 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.